Karolinska Development - Interim report January - September, invitation to conference call Thursday, November 22

STOCKHOLM - November 19, 2012. Karolinska Development will publish its Interim report for January – September 2012 at 08.30 CET on Thursday, November 22. The company will also host a conference call on the same day at 14.00 CET.

Please dial in at the following number a few minutes before the start of the conference call:
+46 (0) 8 566 36 332, from the UK: +44 (0) 207 750 99 50, or from the US: +1 8 666 765 870.

Host: Torbjörn Bjerke, CEO.

For further information, please contact:
Benjamin Nordin, IRO, Karolinska Development AB
Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Today, the portfolio consists of 35 projects, of which 15 are in clinical development. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.